 David Higgins
Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B | 3 | 2023 | 63 | 2.420 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2023 | 367 | 1.260 |
Why?
| | Rural Health Services | 1 | 2024 | 111 | 0.850 |
Why?
| | Hepatitis B Vaccines | 1 | 2023 | 47 | 0.820 |
Why?
| | Sexual Health | 1 | 2023 | 54 | 0.790 |
Why?
| | Gonorrhea | 1 | 2023 | 57 | 0.790 |
Why?
| | Chlamydia Infections | 1 | 2023 | 73 | 0.780 |
Why?
| | Physicians, Primary Care | 1 | 2024 | 230 | 0.740 |
Why?
| | Sexually Transmitted Diseases | 1 | 2023 | 150 | 0.730 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 203 | 0.710 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 194 | 0.650 |
Why?
| | Ventricular Function, Left | 3 | 2024 | 527 | 0.650 |
Why?
| | Mitral Valve Insufficiency | 3 | 2024 | 67 | 0.630 |
Why?
| | HIV Infections | 2 | 2023 | 2720 | 0.610 |
Why?
| | Vaccines | 1 | 2023 | 398 | 0.600 |
Why?
| | Vaccination | 5 | 2024 | 1348 | 0.600 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 754 | 0.540 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 1098 | 0.530 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2017 | 59 | 0.530 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1266 | 0.490 |
Why?
| | Mycobacterium tuberculosis | 5 | 2010 | 308 | 0.480 |
Why?
| | Telemedicine | 1 | 2023 | 788 | 0.460 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2017 | 381 | 0.440 |
Why?
| | Tuberculosis, Pulmonary | 3 | 2010 | 135 | 0.440 |
Why?
| | Hepatitis B Surface Antigens | 2 | 2023 | 18 | 0.430 |
Why?
| | Heart Ventricles | 1 | 2017 | 781 | 0.390 |
Why?
| | Interleukin-10 | 3 | 2014 | 304 | 0.370 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 176 | 0.330 |
Why?
| | Stroke Volume | 3 | 2024 | 592 | 0.330 |
Why?
| | Cross Infection | 1 | 2012 | 218 | 0.330 |
Why?
| | Mitral Valve | 3 | 2024 | 85 | 0.320 |
Why?
| | Implants, Experimental | 1 | 2009 | 19 | 0.320 |
Why?
| | Foreign-Body Reaction | 1 | 2009 | 27 | 0.320 |
Why?
| | Tuberculosis | 3 | 2010 | 272 | 0.300 |
Why?
| | Vitamin D | 1 | 2012 | 384 | 0.300 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2008 | 17 | 0.300 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 147 | 0.280 |
Why?
| | Intensive Care Units | 1 | 2012 | 738 | 0.270 |
Why?
| | Length of Stay | 1 | 2012 | 1127 | 0.260 |
Why?
| | Pregnancy | 3 | 2023 | 6402 | 0.260 |
Why?
| | Female | 16 | 2024 | 68776 | 0.260 |
Why?
| | Critical Illness | 1 | 2012 | 758 | 0.260 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2024 | 185 | 0.250 |
Why?
| | Mass Screening | 2 | 2023 | 1149 | 0.250 |
Why?
| | Humans | 19 | 2024 | 129650 | 0.240 |
Why?
| | Biocompatible Materials | 1 | 2009 | 395 | 0.240 |
Why?
| | Pandemics | 2 | 2023 | 1488 | 0.240 |
Why?
| | Ventricular Function, Right | 2 | 2024 | 276 | 0.230 |
Why?
| | Heart Failure | 1 | 2017 | 2150 | 0.220 |
Why?
| | Blood Coagulation Tests | 1 | 2023 | 60 | 0.210 |
Why?
| | Hepatitis B virus | 1 | 2023 | 35 | 0.210 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2014 | 55 | 0.190 |
Why?
| | Homosexuality, Male | 1 | 2023 | 175 | 0.190 |
Why?
| | HIV | 1 | 2023 | 226 | 0.190 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 1952 | 0.190 |
Why?
| | Infant, Newborn | 2 | 2023 | 5762 | 0.190 |
Why?
| | Ventricular Remodeling | 1 | 2024 | 255 | 0.190 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2023 | 170 | 0.180 |
Why?
| | Exercise Test | 1 | 2024 | 613 | 0.180 |
Why?
| | Retrospective Studies | 4 | 2023 | 14518 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2024 | 868 | 0.170 |
Why?
| | Disease Progression | 3 | 2017 | 2635 | 0.170 |
Why?
| | Macrophages | 1 | 2008 | 1480 | 0.170 |
Why?
| | Child | 5 | 2024 | 20883 | 0.170 |
Why?
| | Infant | 2 | 2024 | 9024 | 0.170 |
Why?
| | Pneumonia, Aspiration | 2 | 2013 | 18 | 0.170 |
Why?
| | Influenza Vaccines | 1 | 2024 | 532 | 0.160 |
Why?
| | Echocardiography | 2 | 2024 | 629 | 0.160 |
Why?
| | Genomics | 1 | 2023 | 716 | 0.150 |
Why?
| | Chemokines, C | 2 | 2008 | 3 | 0.150 |
Why?
| | Hospitals | 1 | 2023 | 637 | 0.150 |
Why?
| | Deglutition Disorders | 2 | 2013 | 134 | 0.140 |
Why?
| | Male | 10 | 2024 | 63681 | 0.140 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 587 | 0.140 |
Why?
| | Ferritins | 1 | 2017 | 58 | 0.140 |
Why?
| | Antiviral Agents | 1 | 2023 | 712 | 0.140 |
Why?
| | United States | 2 | 2024 | 13903 | 0.130 |
Why?
| | Lung | 5 | 2013 | 3930 | 0.130 |
Why?
| | Transforming Growth Factor beta | 2 | 2009 | 457 | 0.120 |
Why?
| | Tracheostomy | 1 | 1997 | 121 | 0.120 |
Why?
| | Adult | 5 | 2024 | 35576 | 0.120 |
Why?
| | Iron | 1 | 2017 | 288 | 0.120 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1279 | 0.120 |
Why?
| | Parents | 1 | 2023 | 1309 | 0.120 |
Why?
| | Colorado | 1 | 2024 | 4421 | 0.110 |
Why?
| | Cytokines | 4 | 2010 | 2017 | 0.110 |
Why?
| | Th1 Cells | 3 | 2010 | 138 | 0.110 |
Why?
| | Primary Health Care | 1 | 2024 | 1680 | 0.110 |
Why?
| | Mice | 9 | 2014 | 16937 | 0.110 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2013 | 22 | 0.110 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1171 | 0.110 |
Why?
| | Propranolol | 1 | 2013 | 50 | 0.110 |
Why?
| | Sialorrhea | 1 | 2013 | 1 | 0.100 |
Why?
| | Interferon-gamma | 4 | 2010 | 770 | 0.100 |
Why?
| | Middle Aged | 4 | 2024 | 31154 | 0.100 |
Why?
| | Neuromuscular Agents | 1 | 2013 | 31 | 0.100 |
Why?
| | Botulinum Toxins, Type A | 1 | 2013 | 41 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2013 | 104 | 0.100 |
Why?
| | Critical Care | 1 | 1997 | 553 | 0.100 |
Why?
| | Biomarkers | 2 | 2017 | 3973 | 0.100 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5406 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 1056 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 317 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 321 | 0.090 |
Why?
| | Prospective Studies | 3 | 2024 | 7133 | 0.090 |
Why?
| | Macrophages, Alveolar | 2 | 2014 | 389 | 0.090 |
Why?
| | Quality of Life | 1 | 2022 | 2704 | 0.090 |
Why?
| | Lymphocyte Activation | 3 | 2010 | 1106 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4897 | 0.090 |
Why?
| | Patient Admission | 1 | 2012 | 182 | 0.090 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 386 | 0.090 |
Why?
| | Animals | 11 | 2014 | 35361 | 0.090 |
Why?
| | Cause of Death | 1 | 2012 | 393 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 157 | 0.080 |
Why?
| | Child, Preschool | 1 | 2024 | 10517 | 0.080 |
Why?
| | Hemorrhage | 1 | 2014 | 678 | 0.080 |
Why?
| | Risk Factors | 1 | 2023 | 9765 | 0.080 |
Why?
| | Neoplasms | 1 | 2023 | 2470 | 0.080 |
Why?
| | Prognosis | 1 | 2017 | 3794 | 0.080 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 300 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1201 | 0.080 |
Why?
| | Oximetry | 1 | 2009 | 87 | 0.080 |
Why?
| | Lymphocyte Subsets | 1 | 2009 | 84 | 0.080 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2008 | 50 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1698 | 0.070 |
Why?
| | Chronic Disease | 3 | 2010 | 1720 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2009 | 1156 | 0.070 |
Why?
| | Cell Count | 1 | 2008 | 314 | 0.070 |
Why?
| | Sepsis | 1 | 2013 | 574 | 0.070 |
Why?
| | Monocytes | 1 | 2010 | 551 | 0.070 |
Why?
| | Granuloma | 1 | 2007 | 89 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 169 | 0.070 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 5440 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2009 | 355 | 0.070 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2008 | 362 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3083 | 0.060 |
Why?
| | Aged | 4 | 2024 | 22103 | 0.060 |
Why?
| | Observer Variation | 2 | 2024 | 315 | 0.060 |
Why?
| | Patient Discharge | 1 | 2012 | 857 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2010 | 2871 | 0.060 |
Why?
| | Adolescent | 1 | 2024 | 20393 | 0.060 |
Why?
| | Prevalence | 1 | 2012 | 2564 | 0.060 |
Why?
| | Fibrosis | 2 | 2023 | 520 | 0.060 |
Why?
| | Dendritic Cells | 1 | 2008 | 478 | 0.060 |
Why?
| | Pneumonia | 1 | 2010 | 616 | 0.060 |
Why?
| | Asymptomatic Diseases | 1 | 2024 | 84 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2008 | 4083 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1838 | 0.050 |
Why?
| | Lung Diseases, Interstitial | 1 | 2009 | 616 | 0.050 |
Why?
| | Cardiac Volume | 1 | 2001 | 12 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 857 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2013 | 10230 | 0.050 |
Why?
| | Precision Medicine | 1 | 2023 | 387 | 0.040 |
Why?
| | Phenotype | 1 | 2008 | 3076 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 268 | 0.030 |
Why?
| | Hemosiderin | 1 | 2014 | 2 | 0.030 |
Why?
| | Bleeding Time | 1 | 2014 | 7 | 0.030 |
Why?
| | Fibrin | 1 | 2014 | 70 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2013 | 90 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 406 | 0.030 |
Why?
| | Myofibroblasts | 1 | 2014 | 121 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1997 | 1434 | 0.030 |
Why?
| | Movement Disorders | 1 | 2013 | 52 | 0.020 |
Why?
| | Intubation, Gastrointestinal | 1 | 2013 | 77 | 0.020 |
Why?
| | Injections | 1 | 2013 | 174 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2024 | 3408 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2013 | 128 | 0.020 |
Why?
| | Patient Care Team | 1 | 1997 | 605 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2014 | 4063 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 769 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2010 | 38 | 0.020 |
Why?
| | Infrared Rays | 1 | 2009 | 21 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 212 | 0.020 |
Why?
| | Cell Polarity | 1 | 2010 | 140 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 298 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 1877 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2013 | 634 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2008 | 315 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 234 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2406 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 190 | 0.020 |
Why?
| | Aerosols | 1 | 2008 | 170 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2008 | 666 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1968 | 0.020 |
Why?
| | Rats | 1 | 2013 | 5500 | 0.010 |
Why?
| | Oxygen | 1 | 2009 | 915 | 0.010 |
Why?
| | Hospitalization | 1 | 2013 | 2070 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5420 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 137 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2008 | 1928 | 0.010 |
Why?
| | Swine | 1 | 2001 | 760 | 0.010 |
Why?
|
|
Higgins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|